Demonetisation hit sales of acute-illness drugs more than chronic ones, study finds
The 2016 cash shortage cut sales of drugs for sudden illnesses by nearly 3.6% relative to drugs for chronic conditions, find economists Anindya S. Chakrabarti, Chirantan Chatterjee and Samarth Gupta.
What happened
Demonetisation made households put off buying medicines for sudden illnesses, argue economists Anindya S. Chakrabarti, Chirantan Chatterjee and Samarth Gupta. On November 8, 2016, ₹500 and ₹1,000 notes, 86% of India's currency by value, stopped being legal tender at four hours' notice. Using monthly pharmacy sales data from 805 drug companies across 31 regions and 18 illness categories, the authors find that sales volume of drugs for acute conditions fell by nearly 3.6%, and value by 3.1%, relative to drugs for chronic conditions. Writing in The Hindu, they draw on forthcoming research in the Journal of Economics and Management Strategy.
Context
Demonetisation was among the largest short-term cash shocks in a cash-reliant economy. Some 99.3% of the withdrawn currency returned, according to Reserve Bank of India data, and interest rates and deposits stayed stable. A 2020 study by Chodorow-Reich and co-authors found the direct effect was a temporary fall in the stock of money. Other countries have since done similar things. Kenya withdrew its old 1,000-shilling note in 2019, and Nigeria replaced its N200, N500 and N1,000 notes in 2022-23; both saw cash shortages.
Why it matters
The finding shows a cash shock can cut essential spending, not only spending on luxuries. The authors explain the result through search costs. Medicines for chronic conditions are bought every month, so buyers have already searched for cheaper options. Medicines for acute illnesses, such as infections or pain, are bought suddenly and with little search. When cash ran short, these unplanned purchases were the ones put off. The authors rule out other explanations. The number of products on sale and the spread of prices did not change, so the fall was not caused by shortages or price rises. Prescription data and disease-outbreak data also showed no break. Where out-of-pocket health spending is high, as in India, cash can be a binding constraint on essential purchases. Areas with fewer public health centres saw larger falls, so public health infrastructure softened the shock.
Impact for India
- Households in under-served regions: they cut acute-drug purchases the most when cash ran short.
- Public health system: areas with more primary health centres were better protected.
- Pharmacies: the authors suggest credit lines or digital payment support at pharmacies during any large currency operation.
- Policymakers and RBI: the authors call for a pre-registered evaluation plan and linked consumption-health data before any such step is taken again.
- Digital payments: UPI at pharmacies, Jan Aushadhi Kendras and AB-PMJAY, all expanded since 2016, should make households more resilient to a similar shock.
Key data
Concepts
Theory lens
Search theory — buyers search for lower prices only while the expected saving is worth the time and effort, so frequent, predictable purchases are searched more than sudden ones. The authors borrow this idea from Alan Sorensen's 2000 study of prescription drug prices. Chronic-condition buyers had already found cheaper options, while acute purchases were unplanned and costly. When demonetisation squeezed cash, households deferred exactly these purchases.
Historical parallel
Kenya's 2019 withdrawal of its old 1,000-shilling note and Nigeria's replacement of its N200, N500 and N1,000 notes in 2022-23 both produced cash shortages similar to India's. The authors use these episodes to argue that demonetisation is not an India-specific experiment, and that the health costs of a cash squeeze are a general lesson for any cash-reliant economy considering currency replacement.
Stakeholders
Practice Question — from the story
With reference to research on the effect of the 2016 demonetisation on medicine purchases, consider the following statements:
- Sales volume of drugs for acute conditions fell by nearly 3.6% relative to drugs for chronic conditions.
- The fall in sales was driven mainly by price rises and by products leaving the market.
Which of the statements given above is/are correct?
Reveal answer & explanation
Answer: 1 only
- Statement 1: Correct. The authors find acute-drug sales fell by nearly 3.6% in volume and 3.1% in value relative to chronic drugs.
- Statement 2: Incorrect. The number of products on sale and the spread of prices did not change; the fall came from households buying less.
Therefore, the correct answer is 1 only.
Concept check — test your understanding
Using search-cost reasoning, why would a sudden cash shortage cut purchases of medicines for acute illnesses more than medicines for chronic conditions?
Reveal answer & explanation
Answer: A
- Search-cost reasoning says repeated buyers have already found cheaper options, so an unexpected, unsearched purchase is the easiest to defer when cash is short.
- The study found that the spread of prices did not change, so a price explanation does not fit.
- Disease-outbreak data showed no break, so a fall in illness does not explain it.
- The number of products on sale did not change, which rules out a supply-side withdrawal by pharmacies.